These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 30561907

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
    Nikiforova MN, Mercurio S, Wald AI, Barbi de Moura M, Callenberg K, Santana-Santos L, Gooding WE, Yip L, Ferris RL, Nikiforov YE.
    Cancer; 2018 Apr 15; 124(8):1682-1690. PubMed ID: 29345728
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
    Selvaggi SM.
    Diagn Cytopathol; 2021 Jul 15; 49(7):838-841. PubMed ID: 33864719
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
    Nikiforova MN, Lepe M, Tolino LA, Miller ME, Ohori NP, Wald AI, Landau MS, Kaya C, Malapelle U, Bellevicine C, Troncone G, Nikiforov YE, Baloch Z.
    Cancer Cytopathol; 2021 Jan 15; 129(1):33-42. PubMed ID: 32697051
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
    Borowczyk M, Szczepanek-Parulska E, Olejarz M, Więckowska B, Verburg FA, Dębicki S, Budny B, Janicka-Jedyńska M, Ziemnicka K, Ruchała M.
    Endocr Pathol; 2019 Mar 15; 30(1):8-15. PubMed ID: 30591992
    [Abstract] [Full Text] [Related]

  • 18. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA, Lozovanu V, Georgescu CE, Georgescu RD, Susman S, Năsui BA, Dobrean A, Silaghi H.
    Front Endocrinol (Lausanne); 2021 Mar 15; 12():649522. PubMed ID: 34054725
    [Abstract] [Full Text] [Related]

  • 19. Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology.
    Velez Torres JM, Curnow PM, Tjendra Y, Jorda M, Fernandez CG, Buitrago MG, Zuo Y, Cordero RR.
    Cancer Cytopathol; 2024 Aug 15; 132(8):491-498. PubMed ID: 38594180
    [Abstract] [Full Text] [Related]

  • 20. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M, Feghali K, Osakwe I.
    Thyroid; 2021 Sep 15; 31(9):1376-1382. PubMed ID: 33764195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.